- Home
- Results news
- Fresita Proteins
- Q2 FY27 results
Fresita Proteins Q2 FY27 results: net profit down 65.0% to ₹0.14 crore, revenue down 81.2%
Fresita Proteins Limited reported standalone Q2 FY27 revenue of ₹0.81 crore, down 81.2% from Q2 FY26, while EBITDA margin rose to 23.4% from 7.0%. Net profit was ₹0.14 crore and basic EPS was ₹0.16; the results were filed after market hours on 30 October 2026.
Key points
- Standalone Q2 FY27 revenue was ₹0.81 crore, down 81.2% from ₹4.30 crore in Q2 FY26 and down 93.8% from ₹12.99 crore in Q1 FY27.
- EBITDA was ₹0.19 crore and the EBITDA margin was 23.4%, compared with ₹0.30 crore and 7.0% in Q2 FY26.
- Net profit was ₹0.14 crore and basic EPS was ₹0.16, against ₹0.40 crore and ₹2.34 in Q2 FY26.
- H1 FY27 total income was ₹19.28 crore, up 25.5% from ₹15.36 crore, while PBT and PAT were ₹2.4 crore and ₹1.8 crore.
- The stock fell 2.0% on the reaction day and was down 4.0% from its pre-results close by the next day's close.
How did Fresita Proteins perform in Q2 FY27?
Fresita Proteins reported standalone revenue from operations of ₹0.81 crore in Q2 FY27, down 81.2% from ₹4.30 crore in Q2 FY26 and 93.8% from ₹12.99 crore in Q1 FY27. Total income was also ₹0.81 crore, against ₹4.41 crore and ₹18.47 crore, respectively. The quarter ended on 30 September 2026.
EBITDA was ₹0.19 crore, down from ₹0.30 crore a year earlier, while the EBITDA margin rose 16.4 percentage points to 23.4% from 7.0%. PBT was ₹0.19 crore, down 52.5% from ₹0.40 crore, and net profit was ₹0.14 crore, down 65.0% from ₹0.40 crore.
Basic EPS was ₹0.16, down 93.2% from ₹2.34 in Q2 FY26 and 91.4% from ₹1.85 in Q1 FY27. Against the previous quarter, EBITDA moved from a loss of ₹3.27 crore to ₹0.19 crore, while PBT fell from ₹2.21 crore to ₹0.19 crore. The filing contains standalone figures; no consolidated figures were given.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 0.81 | 12.99 | 4.30 | −81.2% | −93.8% |
| Other income | 0 | 5.48 | 0.11 | ||
| Total expenses | 0.62 | 16.26 | 4 | −84.5% | −96.2% |
| EBITDA | 0.19 | −3.27 | 0.30 | −36.7% | turned to profit |
| EBITDA margin | 23.4% | -25.2% | 7.0% | +16.4 pp | +48.6 pp |
| Profit before tax | 0.19 | 2.21 | 0.40 | −52.5% | −91.4% |
| Tax | 0.05 | 0.55 | 0 | −90.9% | |
| Net profit | 0.14 | 1.66 | 0.40 | −65.0% | −91.6% |
| EPS (₹) | 0.16 | 1.85 | 2.34 | −93.2% | −91.4% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Fresita Proteins' costs and profit?
Total expenses fell to ₹0.62 crore in Q2 FY27 from ₹4 crore in Q2 FY26, a decrease of ₹3.38 crore or 84.5%. Employee cost rose by ₹0.12 crore to ₹0.13 crore, while other expenses increased by ₹0.07 crore to ₹0.20 crore. Cost of materials, finance costs and depreciation were unchanged, and there was no exceptional item.
Other income fell by ₹0.11 crore, from ₹0.11 crore in Q2 FY26 to no exceptional item in the quarter. Tax expense increased by ₹0.05 crore, from no exceptional item to ₹0.05 crore. PBT consequently declined by ₹0.21 crore to ₹0.19 crore, while net profit fell by ₹0.26 crore to ₹0.14 crore.
Against Q1 FY27, total expenses fell by ₹15.64 crore to ₹0.62 crore and other expenses declined by ₹6.24 crore to ₹0.20 crore. However, other income fell by ₹5.48 crore and tax expense declined by ₹0.50 crore. Employee cost was ₹0.13 crore, up ₹0.01 crore, while cost of materials, finance costs and depreciation were unchanged.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 0 | 0 | 0 | |
| Employee cost | 0.13 | 0.01 | +0.12 | +1200.0% |
| Finance costs | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | |
| Other expenses | 0.20 | 0.13 | +0.07 | +53.8% |
| Total expenses | 0.62 | 4 | −3.38 | −84.5% |
| Other income | 0 | 0.11 | −0.11 | |
| Tax | 0.05 | 0 | +0.05 |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
In H1 FY27, revenue from operations was ₹13.8 crore, down 9.6% from ₹15.26 crore in H1 FY26. Total income was ₹19.28 crore, up 25.5% from ₹15.36 crore, with other income of ₹5.48 crore in the first half compared with ₹0.11 crore a year earlier.
PBT moved to ₹2.4 crore from a loss of ₹0.09 crore, while PAT was ₹1.8 crore against a loss of ₹0.09 crore. Basic EPS for the half was ₹2.00, compared with a loss of ₹0.51 in H1 FY26. The company reported standalone results for the quarter and half year ended 30 September 2026.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 13.80 | 15.26 | −9.6% |
| Profit before tax | 2.40 | −0.09 | turned to profit |
| Net profit | 1.80 | −0.09 | turned to profit |
| EPS (₹) | 2.00 | −0.51 |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
Total assets increased to ₹99.84 crore at 30 September 2026 from ₹86.61 crore at 31 March 2026, and total equity rose to ₹88.01 crore from ₹3.02 crore. Borrowings were unchanged at ₹0.15 crore, while cash and cash equivalents fell to ₹0.02 crore from ₹7.51 crore. Trade receivables increased to ₹24.77 crore from ₹4.27 crore.
H1 FY27 operating cash flow was negative ₹7.49 crore, compared with negative ₹82.59 crore in H1 FY26. Investing cash flow was negative ₹0.01 crore against positive ₹82.69 crore, and financing cash flow was negative ₹0.00 crore, unchanged from the earlier period. Capital expenditure was ₹0.01 crore, against no exceptional item in H1 FY26.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 99.84 | 86.61 |
| Total equity | 88.01 | 3.02 |
| Borrowings | 0.15 | 0.15 |
| Cash and equivalents | 0.02 | 7.51 |
| Inventories | 0 | 0 |
| Trade receivables | 24.77 | 4.27 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | −7.49 | −82.59 |
| Cash from investing | −0.01 | 82.69 |
| Cash from financing | 0 | 0 |
| Capital expenditure | 0.01 | 0 |
Source: Company's results filing (XBRL).
How has Fresita Proteins done over the last 8 quarters?
Revenue has been uneven across the reported quarters. It peaked at ₹24.05 crore in Q3 FY25 and fell to ₹0.81 crore in Q2 FY27, after ₹12.99 crore in Q1 FY27. Profit moved from a net loss of ₹0.49 crore in Q1 FY26 to net profit of ₹1.66 crore in Q1 FY27, then eased to ₹0.14 crore in Q2 FY27.
The EBITDA margin bottomed at negative 47.2% in Q3 FY26 and peaked at 92.6% in Q4 FY26. It was negative 25.2% in Q1 FY27 before rising to 23.4% in Q2 FY27. No streak is provided for the reported quarterly series.
What else did the company announce?
The board approved the unaudited standalone financial results for the quarter and half year ended 30 September 2026, together with the limited review report. It also approved a proposal to shift the registered office from Alwar, Rajasthan, to Rajkot, Gujarat, subject to shareholder and other statutory and regulatory approvals.
A same-day rights-issue filing proposed the issue of up to 74,79,917 fully paid equity shares of ₹10 each at ₹120 per share, aggregating up to ₹89.76 crore. Eligible shareholders would receive five rights shares for every six fully paid-up shares held on the record date, 30 October 2026. The issue was scheduled to open on 12 November 2026 and close on 27 November 2026.
How did Fresita Proteins shares react?
Fresita Proteins’ shares fell 2.0% on the reaction day from the pre-results close of ₹125.05. By the next day’s close, the stock was down 4.0% from that pre-results close; no five-day move was available. The filing appeared after market hours.
| After the filing | Stock |
|---|---|
| Reaction day | −2.0% |
| Next day | −4.0% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
Quick answers
What was Fresita Proteins' revenue in Q2 FY27?
Revenue from operations was ₹0.81 crore, down 81.2% from ₹4.30 crore in Q2 FY26 (standalone).
Did Fresita Proteins make a profit in Q2 FY27?
Yes. Net profit was ₹0.14 crore, against a net profit of ₹0.40 crore in Q2 FY26.
What was Fresita Proteins' EPS in Q2 FY27?
Basic earnings per share were ₹0.16, against ₹2.34 in Q2 FY26.
How did Fresita Proteins shares react to the Q2 FY27 results?
On the reaction day the stock moved −2.0% from the previous close.
When did Fresita Proteins announce its Q2 FY27 results?
On 30 October 2026, in a filing to the BSE.
Sources
- Board Meeting Intimation for Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (BSE, 23 October 2026) · PDF
- Board Meeting Outcome for Outcome Of Board Meeting Held On 30Th October, 2026 Pursuant To Regulation 30 And Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (BSE, 30 October 2026) · PDF
- Results Financial_Result_30_09_2026 (BSE, 30 October 2026) · PDF
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.